Advanced Human Imaging Limited Sponsored ADR AHI

1.50 0.00 0.00% as of 14 Aug
Market cap
$13.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 68.54%

Capital & Financial Ratios

Market Cap 13.15
Revenue 0.58
Net Income (23.20)
Free Cash Flow (18.23)
Net Debt 2.04
Current Ratio 0.20
Debt/Equity (1.14)
P/E ratio 0.00
P/S ratio 44.05
P/B ratio 0.00
Past 5Y EPS Growth 23.26%
This Y EPS Growth —
Next Y EPS Growth —
Next 5Y EPS Growth —
in millions of $

Dividends

Payout Ratio 0.00
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2021 2022 2023 Q'23
Cash 2 4 1 0
Receivables 0 0 0 0
Inventory — — — —
Other — — — —
4 5 2 1
2021 2022 2023 Q'23
Payables 1 0 2 3
ST’ Debt 2 1 1 1
Other 1 1 0 1
3 1 4 5
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — 9.59% 41.21%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 21.50% 43.45%

Revenue

Mar Jun Sep Dec Year
’26 — — — — —
’23 — — — — 2
’22 — — — — 0
’21 — — — — 1
’20 — — — 0 1
’19 — 0 — — 0
in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — — — (3) —
’23 — (5) — (3) (5)
’22 — (7) — (3) (7)
’21 — (4) — (1) (4)
’20 — (3) — (1) (3)
’19 — (1) — — (2)
’18 — — — — (1)
in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

Mar Jun Sep Dec Year
’26 — — — (3) —
’23 — (5) — (3) (5)
’22 — (7) — (3) (7)
’21 — (4) — (1) (4)
’20 — (3) — (1) (3)
’19 — (1) — — (2)
’18 — — — — (1)
in millions of $ · fiscal quarters ending in the months shown

EPS

Mar Jun Sep Dec Year
’26 — — — — —
’23 — — — — (1.31)
’22 — — — — (2.66)
’21 — — — — (3.14)
’20 — — — (0.02) (1.44)
’19 — (0.02) — — (0.03)
’18 — — — — (0.13)
fiscal quarters ending in the months shown

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
— — — — — — — 12.16 1.40 0.64

Analyst estimates 2024–2026

Powerpack
Low Price
— — — — — — — 31.08 20.92 15.52
High Price
— — — — — — — 19 19 32
Employees
— — — — 0 0 0 0 0 0
Revenue/Emp
— — — — 1 0 1 1 0 2
Revenue
— — — 0.00% 88.39% 0.00% 100.00% 100.00% 100.00% 100.00%
Gross Margin
— — — (2) (11) (4) (6) (15) (15) (9)
EBT
— — — 0.00% (921.85%) (122,443.48%) (908.68%) (1,234.75%) (4,731.42%) (459.69%)
EBT Margin
— — — 0 (10) (3) (5) (14) (15) (9)
Net Income
— — — 0 0 0 0 0 0 0
Depreciation
— — — 0.00 0.10 0.00 0.18 0.27 0.06 0.28
Revenue/Sh
— — — (0.02) (0.13) (0.03) (1.44) (3.14) (2.66) (1.24)
Earnings/Sh
— — — (0.11) (0.08) (0.64) (0.72) (0.92) (1.30) (0.75)
Cash Flow/Sh
— — — 0.00 0.00 0.00 (0.02) (0.01) (0.01) (0.01)
Capex/Sh
— — — (0.11) (0.08) (0.64) (0.74) (0.92) (1.32) (0.76)
Free CF/Sh
— — — 0.14 0.04 0.11 0.12 0.44 1.13 0.21
Book Value/Sh
— — — 13 12 4 4 4 5 7
Shares
— — — — 0.00 0.00 0.00 0.00 0.00 0.00
PE Ratio
— — — — 519.26 519.26 519.26 519.26 66.00 112.47
PS Ratio
— — — — 145.13 145.13 145.13 145.13 6.34 47.60
PB Ratio
— — — — 519.37 519.37 519.37 519.37 60.12 112.04
EV/Sales
— — — — (32.09) (32.09) (32.09) (32.09) (2.41) (3.66)
EV/FCF
— — — (1) (1) (2) (3) (4) (7) (5)
Op' Cash Flow
— — — (1) 0 0 0 0 0 0
Capex
— — — (1) (1) (2) (3) (4) (7) (5)
FCF
— — — 1 0 (1) (1) 1 4 (2)
Working Cap'
— — — — 0 1 1 2 1 1
Total Debt
— — — (1) 0 1 1 0 (4) 0
Net Debt
— — — 2 1 0 0 2 6 1
Sh' Equity
— — — (90.94%) (1,384.20%) (183.02%) (225.12%) (335.76%) (221.40%) (125.76%)
ROA
— — — 0.00% 0.00% 0.00% (318.73%) (449.56%) (358.47%) (474.08%)
ROIC
— — — (138.90%) (850.28%) (677.61%) (1,275.35%) (1,152.26%) (355.91%) (228.08%)
ROE
predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Jun 2023 · latest quarter Dec 2019

Advanced Human Imaging Limited Sponsored ADR (AHI) key facts

  • Advanced Human Imaging Limited Sponsored ADR (AHI) is a Software Application company in the Technology sector, traded in the US as an ADR.
  • Advanced Human Imaging Limited Sponsored ADR’s revenue for fiscal 2023 (year ended June 2023) was AUD 1.9 million, up 484.3% from fiscal 2022.
  • As of August 14, 2025, AHI traded at $1.50, a market capitalization of $13.2 million.
  • Return on equity was −228.1% and debt-to-equity -1.14.

Source: company filings (standardised) and stockrow calculations.

Advanced Human Imaging Limited Sponsored ADR (AHI) Latest News

News by impact score

Fine-tune

22 Jan

3

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on January 24th & 25th at 9:00 A.M. ET. The conference may moderately influence AHI's future performance and market sentiment.

18 Jan

4

AHI CEO to present at Microcap Conference in Atlantic City, discussing digital health solutions and commercial partnerships. Significant impact expected on AHI's future with updates on technology, partnerships, and commercial milestones.

3 Nov

4

AHI signs binding term sheet with OneClinic for Vietnam to integrate biometric health assessment capabilities into OneClinic's digital health record system. The partnership with OneClinic and the potential launch of the integrated solution in Vietnam could significantly impact AHI's future market performance.

19 Oct

4

Dr. Walid Abbas Zaher honored as a top healthcare leader by Forbes Middle East for his contributions to healthcare and clinical research. The collaboration between AHI and IntelliGen led by Dr. Zaher is expected to have a significant impact on healthcare solutions and standards in the Middle East.

9 Oct

4

AHI partner Bearn LLC collaborates with OnCore Innovations Inc. to integrate biometrics into golf experience for health benefits. The collaboration between Bearn and OnCore Innovations is expected to have a significant impact on AHI's future by integrating biometrics into the golfing experience for health benefits.

27 Sep

4

AHI partner Bearn LLC signs commercial partnership with AIG Insurance to streamline underwriting solutions and reward users for better health outcomes. The partnership with AIG has the potential to significantly impact AHI's future market performance and strategic positioning.

20 Sep

4

AHI signs LOI with Unisure and SCOR to develop digital underwriting solution for insurance industry. Partnership with major players in insurance industry expected to significantly impact AHI's future and market performance.

13 Sep

4

AHI selected as finalist for Singapore Ministry of Health project. AHI's participation in the project could significantly impact its future trajectory and market performance.

12 Sep

4

Advanced Health Intelligence Ltd secures $1.5M funding via convertible loan facility, with potential to increase to $5M. Terms include 24-month maturity, 10% interest, and conversion to shares at A$0.30/share. The funding secured through the convertible loan facility has the potential to significantly impact AHI's future financial performance and strategic direction.

8 Sep

4

AHI collaborates with Bin Farhood Group to deploy technology in MENA region. The collaboration is expected to have a significant impact on AHI's future growth and market performance.

17 Aug

4

Advanced Health Intelligence Ltd obtains 43.5% reimbursement for overseas R&D under Australia's R&DTI scheme, enabling further global innovation and talent acquisition. Significant impact expected on AHI's future growth, innovation, and global competitiveness.

14 Aug

4

Advanced Health Intelligence Ltd signs collaboration agreement with IntelliGen FZ-LLC. The collaboration agreement with IntelliGen FZ-LLC is a significant move that could alter AHI's trajectory and market sentiment.

2 Aug

4

AHI signs exclusive license deal with Changlin Network Technology Ltd to bring digital healthcare solutions to China. The exclusive license deal with Changlin has the potential to significantly impact AHI's future market performance and strategic positioning.

1 Aug

4

AHI reported strong financial progress and partnerships in Q2 2023, including FDA submissions, NASDAQ compliance, debt reduction, and $5m placement. Expanded capabilities showcased at BCG summit. New biometric health assessment offering. Partner-friendly delivery methods introduced. Cost consolidation achieved. Funding proposals received post-quarter. Significant impact likely on future and performance with transformative initiatives, partnerships, and financial progress.

5 Jul

4

Advanced Health Intelligence Ltd provides shareholder update on smartphone-based biometric health assessment and collaboration with Stellenbosch University. FDA submissions underway for BodyScan categorization. The collaboration with Stellenbosch University and FDA submissions for BodyScan categorization are significant developments that could have a major impact on AHI's future and market performance.

29 Jun

4

Advanced Health Intelligence Ltd announces implementation of ADS ratio change. The ratio change is expected to have a significant impact on the company's future performance and market dynamics.

1 May

4

AHI completes integration of acquired platforms, releases new biometric health assessment software, receives funding, updates on commercial partners, and reports highest quarterly revenue. Significant impact likely on future and performance due to strategic moves, new product offerings, revenue growth, and partnerships.

stockrow.com/AHI · Data as of Dec 31, 2019 · For information only; not investment advice. · © 2026 stockrow.com